» Download Public Reports
About 1 500 reports
- Country report
- April 2013
- 10 pages
May 2013
... Involved, even indirectly, with an important therapeutic area that addresses the needs of millions of patients who suffer from respiratory disease is particularly meaningful to all of us at elan." Relvar ...
April 2013
... acute myocardial infarction in ireland. It also aimed to estimate the budget impact of adding omacor to current secondary prevention therapy following acute myocardial infarction. Evidence on the cost ...
May 2013
... That dicobalt edetate only be given when the patient is tending to lose or has lost consciousness. Distamine penicillamine a disease modifying antirheumatic drug (dmard) used for the treatment of rheumatoid ...
April 2013
... Control: access to medicines access to partially compensated medicines since 2005 full coverage of diabetes, psychotropic drugs, partial coverage for cardio-vascular drugs positive list 2011: 92 ...
April 2013
... Of a pathologic oxygen supply dependency remains contro- versial. Study objective: to evaluate the relationship between oxygen delivery (do2) and oxygen consumption (vo2) during severe sepsis and to compare ...
May 2013
... To prevent or delay the onset and progression of diabetes and its complications. gestational diabetes mellitus (gdm) Diagnosed during pregnancy Affects at least 7% and possibly as many as 18% of u ...
April 2013
... Nonsurgical polyp removal complete colonic examination age 35 years or older; no history of colorectal cancer, inflammatory bowel disease, or large bowel resection; satisfactory completion of a food ...
April 2013
... Official figures show. Circulatory conditions like heart disease remain the most common cause of death, contributing to a third of the deaths registered. But over the decade, mortality from ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 800 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...